TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

REFINE THE APPROACH

The first and only monoclonal antibody (mAb) for HAE1

TAKHZYRO provides targeted inhibition of plasma kallikrein, a critical regulator of bradykinin production, to help prevent HAE attacks.1

UNTREATED PATIENT

Image showing when C1-INH is deficient or dysfunctional, plasma kallikrein activity is increased. This leads directly to excessive bradykinin production and, ultimately, HAE attacks.

HAE attack

When C1-INH is deficient or dysfunctional, plasma kallikrein activity is increased.1 This leads directly to excessive bradykinin production and, ultimately, HAE attacks1

PATIENT TREATED WITH TAKHZYRO

Image showing how TAKHZYRO provides direct inhibition of plasma kallikrein to control excess bradykinin production.

Prevention of attacks

Direct inhibition of plasma kallikrein controls excess bradykinin production1

HMWK=high molecular weight kininogen.
cHMWK=cleaved high molecular weight kininogen.

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Watch TAKHZYRO in action

TAKHZYRO is a first-of-its-kind mAb preventive treatment for HAE.1 Use this video to help explain what makes TAKHZYRO different to your patients.

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp. (a wholly-owned, indirect subsidiary of Shire plc) at 1–800–828–2088, or FDA at 1–800–FDA–1088 or www.fda.gov/medwatch.

Please see full Prescribing Information here.

Reference: 1. TAKHZYRO (lanadelumab-flyo) [prescribing information]. Lexington, MA: Shire LLC; 2018.